AMERICAN SOCIETY OF CLINICAL ONCOLOGY

AstraZeneca's Imfinzi approved in the US for limited-stage small cell lung cancer (LS-SCLC) after chemotherapy and radiation, based on ADRIATIC trial results showing improved survival and reduced risk of death and disease progression.

AstraZeneca's IMFINZI® (durvalumab) approved in the US for limited-stage small cell lung cancer (LS-SCLC) post concurrent platinum-based chemotherapy and radiation therapy, based on ADRIATIC Phase III trial results showing a 27% reduction in the risk of death versus placebo.

Florida Cancer Specialists & Research Institute, LLC (FCS) presents breakthrough research on blood cancers at the 2024 American Society of Hematology Annual Meeting. FCS Director of Drug Development Manish Patel, MD, highlights transformative research advancing next-gen therapies, with over 130 clinical trials available. Co-authored abstracts by FCS hematologists and medical oncologists will be presented, including studies on PRT543, AC676, and belantamab mafodotin. The FCS Real-World Evidence team also presents a study on frontline treatment patterns in newly diagnosed multiple myeloma.

FDA fast track designation granted to CRB-701, a Nectin-4–directed ADC for R/R metastatic cervical cancer. Phase 1/2 trial (NCT06265727) ongoing, evaluating safety, PK, and efficacy in high Nectin-4 expression solid tumors. First data expected early 2025. CRB-701 showed promising antitumor responses and was generally well-tolerated in phase 1 findings.

The FDA approved durvalumab (Imfinzi) for limited-stage small cell lung cancer (SCLC) not progressing after platinum-based chemoradiation, based on the phase III ADRIATIC trial. The trial showed a significant improvement in median overall survival from 33.4 to 55.9 months with durvalumab compared to placebo, and a median progression-free survival increase from 9.2 to 16.6 months. Durvalumab is now considered the new standard of care for this condition.

The FDA approved durvalumab (Imfinzi) for limited-stage small cell lung cancer (LS-SCLC) after chemotherapy and radiation, based on the ADRIATIC trial results. Durvalumab, a PD-L1 inhibitor, is also approved for other cancers, offering a significant treatment option for LS-SCLC patients.

IMFINZI® (durvalumab) approved in the US for limited-stage small cell lung cancer (LS-SCLC) post-chemoradiation, based on ADRIATIC Phase III trial showing 27% reduction in death risk versus placebo, with 57% survival at three years.

AstraZeneca's IMFINZI® (durvalumab) approved by the FDA for treating limited-stage small cell lung cancer (LS-SCLC) after platinum-based chemotherapy and radiation therapy. The approval is based on the ADRIATIC Phase III trial results, showing improved survival rates and reduced risk of death and disease progression. IMFINZI is the first systemic treatment to demonstrate improved survival for LS-SCLC patients post-curative-intent chemoradiotherapy, with 57% of patients alive at three years. The drug also received approval in Switzerland and is under review in the EU, Japan, and other countries.

AstraZeneca's Imfinzi approved in the US for limited-stage small cell lung cancer, showing a 27% reduction in death risk in the ADRIATIC Phase III trial. Imfinzi is the first immunotherapy regimen for this condition, with 57% of patients alive at three years.

FDA approves durvalumab (Imfinzi) for limited-stage small cell lung cancer (SCLC) post-platinum-based chemoradiotherapy, supported by phase 3 ADRIATIC study. Durvalumab reduced risk of death by 27% and disease progression by 24%, establishing a new standard of care.